» Articles » PMID: 31700665

Statistical Analysis of Single-copy Assays when Some Observations Are Zero

Overview
Journal J Virus Erad
Date 2019 Nov 9
PMID 31700665
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Observational and interventional studies for HIV cure research often use single-copy assays to quantify rare entities in blood or tissue samples. Statistical analysis of such measurements presents challenges due to tissue sampling variability and frequent findings of 0 copies in the sample analysed. We examined four approaches to analysing such studies, reflecting different ways of handling observations of 0 copies: (A) replace observations of 0 copies with 1 copy; (B) add 1 to all observed numbers of copies; (C) treat observations of 0 copies as left-censored at 1 copy; and (D) leave the data unaltered and apply a method for count data, negative binomial regression. Because research seeks to estimate general patterns rather than individuals' values, we argue that unaltered use of 0 copies is suitable for research purposes and that altering those observations can introduce bias. When applied to a simulated study comparing preintervention to postintervention measurements within 12 participants, methods A-C showed more attenuation than method D in the estimated intervention effect, less chance of finding  < 0.05 for the intervention effect and a lower chance of including the true intervention effect within the 95% confidence interval. Application of the methods to actual data from a study comparing multiply-spliced HIV RNA among men and women estimated smaller differences by methods A-C than by method D. We recommend that negative binomial regression, which is readily available in many statistical software packages, be considered for analysis of studies of rare entities that are measured by single-copy assays.

Citing Articles

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.

Scully E, Aga E, Tsibris A, Archin N, Starr K, Ma Q Clin Infect Dis. 2022; 75(8):1389-1396.

PMID: 35176755 PMC: 9555843. DOI: 10.1093/cid/ciac136.


Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.

Uldrick T, Adams S, Fromentin R, Roche M, Fling S, Goncalves P Sci Transl Med. 2022; 14(629):eabl3836.

PMID: 35080914 PMC: 9014398. DOI: 10.1126/scitranslmed.abl3836.


Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy.

Stern J, Solomon A, Dantanarayana A, Pascoe R, Reynaldi A, Davenport M J Infect Dis. 2021; 225(10):1721-1730.

PMID: 34655216 PMC: 9633724. DOI: 10.1093/infdis/jiab533.


Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy.

Bakkour S, Deng X, Bacchetti P, Grebe E, Montalvo L, Worlock A J Clin Microbiol. 2020; 58(12).

PMID: 32967900 PMC: 7685884. DOI: 10.1128/JCM.01400-20.


Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.

Peluso M, Bacchetti P, Ritter K, Beg S, Lai J, Martin J JCI Insight. 2020; 5(4).

PMID: 32045386 PMC: 7101154. DOI: 10.1172/jci.insight.132997.

References
1.
Amrhein V, Greenland S, McShane B . Scientists rise up against statistical significance. Nature. 2019; 567(7748):305-307. DOI: 10.1038/d41586-019-00857-9. View

2.
Elliott J, McMahon J, Chang C, Lee S, Hartogensis W, Bumpus N . Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015; 2(12):e520-9. PMC: 5108570. DOI: 10.1016/S2352-3018(15)00226-X. View

3.
Palmer S, Wiegand A, Maldarelli F, Bazmi H, Mican J, Polis M . New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003; 41(10):4531-6. PMC: 254331. DOI: 10.1128/JCM.41.10.4531-4536.2003. View

4.
Scully E, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C . Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. J Infect Dis. 2018; 219(7):1084-1094. PMC: 6784502. DOI: 10.1093/infdis/jiy617. View

5.
Sogaard O, Graversen M, Leth S, Olesen R, Brinkmann C, Nissen S . The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog. 2015; 11(9):e1005142. PMC: 4575032. DOI: 10.1371/journal.ppat.1005142. View